GGrantIndex
← Leaderboards

Eduard A. Sergienko

Mayo Clinic Arizona

$20,721,252
Attributed
$28,470,365
Total exposure
9
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$28,470,365 · 9

By mechanism

R01$15,724,141 · 8
U54$12,746,224 · 1

Most similar at Mayo Clinic Arizona

Same institution · by research overlap

Others in their field

Top investigators on “Analog

Research focus

AnalogScaffoldValidationHigh Throughput ScreeningFutureResponseCellsScreeningDoseProteinsBindingSmall MoleculePathway InteractionsBiochemicalPowder Dose FormCancer CellInhibitorPharmaceutical PreparationsClinical TrialsScale UpCheminformaticsAffectProductionEnzymes

Grant awards (31)

Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer$809,248
R01 · FY2025 · CA
Screening for Inhibitors of the Chromatin Reader SGF29$768,437
R01 · FY2025 · CA
Identification of small molecule inhibitors of the DDI2 protease$699,304
R01 · FY2025 · CA
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer$538,890
R01 · FY2025 · CA · contact PI
Activation of the Secretin Receptor as a Strategy for the Treatment of Heart Failure$454,632
R01 · FY2025 · HL
Identification of small molecule inhibitors of the DDI2 protease$77,925
R01 · FY2025 · CA
Discovery of Potent Selective Inhibitors of the Histone Methyltransferase SUV39H1 for the Treatment of Cancer$809,234
R01 · FY2024 · CA
Identification of small molecule inhibitors of the DDI2 protease$671,643
R01 · FY2024 · CA
Activation of the Secretin Receptor as a Strategy for the Treatment of Heart Failure$631,842
R01 · FY2024 · HL
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer$577,198
R01 · FY2024 · CA · contact PI
Identification of small molecule inhibitors of the DDI2 protease$77,925
R01 · FY2024 · CA
Discovery of Selective Inhibitors for the EphA4 Kinase$760,964
R01 · FY2023 · AG · contact PI
Identification of small molecule inhibitors of the DDI2 protease$730,979
R01 · FY2023 · CA
Activation of the Secretin Receptor as a Strategy for the Treatment of Heart Failure$605,207
R01 · FY2023 · HL
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer$599,074
R01 · FY2023 · CA · contact PI
Discovery of Selective Inhibitors for the EphA4 Kinase$757,556
R01 · FY2022 · AG · contact PI
Activation of the Secretin Receptor as a Strategy for the Treatment of Heart Failure$609,636
R01 · FY2022 · HL
Discovery of Glutaryl-CoA Dehydrogenase inhibitors for melanoma and pancreatic cancer$569,944
R01 · FY2022 · CA · contact PI
Identification of small molecule modulators of mitochondrial creatine kinase 1$491,439
R01 · FY2022 · CA · contact PI
Discovery of Selective Inhibitors for the EphA4 Kinase$754,237
R01 · FY2021 · AG · contact PI
Identification of small molecule modulators of mitochondrial creatine kinase 1$496,612
R01 · FY2021 · CA · contact PI
Discovery of Selective Inhibitors for the EphA4 Kinase$751,756
R01 · FY2020 · AG · contact PI
Identification of small molecule modulators of mitochondrial creatine kinase 1$520,361
R01 · FY2020 · CA · contact PI
High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1$648,006
R01 · FY2018 · CA
High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1$678,423
R01 · FY2017 · CA
High Throughput Screening to Discover Chemical Inhibitors of Quiescin Sulfhydryl Oxidase 1$633,669
R01 · FY2016 · CA
Assay Development$2,625,600
U54 · FY2012 · HG · contact PI
Assay Development$2,631,289
U54 · FY2011 · HG · contact PI
Assay Development$2,536,221
U54 · FY2010 · HG · contact PI
Assay Development$2,557,977
U54 · FY2009 · HG · contact PI
Assay Development$2,395,137
U54 · FY2008 · HG · contact PI